{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:54:43Z","timestamp":1769014483056,"version":"3.49.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11064-024-04172-2","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T07:05:31Z","timestamp":1717484731000},"page":"1945-1964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neurochemical Anatomy of Cushing\u2019s Syndrome"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-3525","authenticated-orcid":false,"given":"Robert","family":"Lalonde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-3920","authenticated-orcid":false,"given":"Catherine","family":"Strazielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"4172_CR1","doi-asserted-by":"publisher","unstructured":"Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, Webb SM, Biermasz NR, van der Wee NJA, Pereira AM (2015) Cushing\u2019s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173:R1-14. https:\/\/doi.org\/10.1530\/EJE-14-1101. PMID: 25650405","DOI":"10.1530\/EJE-14-1101"},{"key":"4172_CR2","doi-asserted-by":"publisher","unstructured":"Eviz E, Yesiltepe Mutlu G, Arduc Akcay A, Erbey F, Guran T, Hatun TS (2023) An overlooked manifestation of hypercortisolism - cerebral cortical atrophy and challenges in identifying the etiology of hypercortisolism: a report of 2 pediatric cases. Horm Res Paediatr in press. https:\/\/doi.org\/10.1159\/000530391. PMID: 36972563","DOI":"10.1159\/000530391"},{"key":"4172_CR3","doi-asserted-by":"publisher","unstructured":"Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A (2019) Advances in the medical treatment of Cushing\u2019s syndrome. Lancet Diabetes Endocrinol 7:300\u2013312. https:\/\/doi.org\/10.1016\/S2213-8587(18)30155-4. PMID: 30033041","DOI":"10.1016\/S2213-8587(18)30155-4"},{"key":"4172_CR4","doi-asserted-by":"publisher","unstructured":"Komori T, Martin WH, Graber AL, Delbeke D (2002) Serendipitous detection of Cushing\u2019s disease by FDG positron emission tomography and a review of the literature. Clin Nucl Med 27:176\u2013178. https:\/\/doi.org\/10.1097\/00003072-200203000-00005. PMID: 11852303","DOI":"10.1097\/00003072-200203000-00005"},{"key":"4172_CR5","doi-asserted-by":"publisher","unstructured":"Kovacs K (1993) The pathology of Cushing\u2019s disease. J Steroid Biochem Mol Biol 45:179\u2013182. https:\/\/doi.org\/10.1016\/0960-0760(93)90139-n. PMID: 8481343","DOI":"10.1016\/0960-0760(93)90139-n"},{"key":"4172_CR6","doi-asserted-by":"publisher","unstructured":"Krieger DT (1983) Physiopathology of Cushing\u2019s disease. Endocr Rev 14:22\u201343. https:\/\/doi.org\/10.1210\/edrv-4-1-22. PMID: 6131818","DOI":"10.1210\/edrv-4-1-22"},{"key":"4172_CR7","doi-asserted-by":"publisher","unstructured":"Meyer JS (1985) Biochemical effects of corticosteroids on neural tissues. Physiol Rev 65:946\u20131020. https:\/\/doi.org\/10.1152\/physrev.1985.65.4.946. PMID: 2414792","DOI":"10.1152\/physrev.1985.65.4.946"},{"key":"4172_CR8","doi-asserted-by":"publisher","unstructured":"Nieman LK, Ilias I (2005) Evaluation and treatment of Cushing\u2019s syndrome. Am J Med 118:1340\u20131346. https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.059. PMID: 16378774","DOI":"10.1016\/j.amjmed.2005.01.059"},{"key":"4172_CR9","doi-asserted-by":"publisher","unstructured":"Morris D, Grossman A (2002) The medical management of Cushing\u2019s syndrome. Ann NY Acad Sci 970:119\u2013133. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04418.x. PMID: 12381547","DOI":"10.1111\/j.1749-6632.2002.tb04418.x"},{"key":"4172_CR10","doi-asserted-by":"publisher","unstructured":"Newell-Price J, Bertagna X, Grossman ABLK, Nieman LK (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617. https:\/\/doi.org\/10.1016\/S0140-6736(06)68699-6. PMID: 16698415","DOI":"10.1016\/S0140-6736(06)68699-6"},{"key":"4172_CR11","doi-asserted-by":"publisher","unstructured":"Shukla J, Vatsa R, Walia R, Chhabra A, Rana N, Singh H, Kumar R, Mittal BR (2021) Development of 68Ga DOTA-CRH for PET\/CT imaging of ACTH-dependent Cushing\u2019s disease: Initial study. Cancer Biother Radiopharm 36:642\u2013650. https:\/\/doi.org\/10.1089\/cbr.2020.4686. PMID: 34191604","DOI":"10.1089\/cbr.2020.4686"},{"key":"4172_CR12","doi-asserted-by":"publisher","unstructured":"Sonino N, Boscaro M, Fallo F (2005) Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol 4:87\u201394. https:\/\/doi.org\/10.2165\/00024677-200504020-00003. PMID: 15783246","DOI":"10.2165\/00024677-200504020-00003"},{"key":"4172_CR13","doi-asserted-by":"publisher","unstructured":"Xin C, Rui-xue C, Hui P, Tao Y, Hui-Juan Z, Fang L (2011) Value of [18F] fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in diagnosis and localization of Cushing\u2019s disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 33:107\u2013110. https:\/\/doi.org\/10.3881\/j.issn.1000-503X.2011.02.001. PMID: 21529433","DOI":"10.3881\/j.issn.1000-503X.2011.02.001"},{"key":"4172_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0960-0760(90)90489-8","volume":"37","author":"ER de Kloet","year":"1990","unstructured":"de Kloet ER, Reul JM, Sutanto W (1990) Corticosteroids and the brain. J Steroid Biochem Mol Biol 37:387\u2013394. https:\/\/doi.org\/10.1016\/0960-0760(90)90489-8PMID: 2257242","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4172_CR15","doi-asserted-by":"publisher","unstructured":"McEwen BS, Davis PG, Parsons B, Pfaff DW (1979) The brain as a target for steroid hormone action. Ann Rev Neurosci 2:65\u2013112. https:\/\/doi.org\/10.1146\/annurev.ne.02.030179.000433. PMID: 395885","DOI":"10.1146\/annurev.ne.02.030179.000433"},{"key":"4172_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.steroids.2014.08.014","volume":"91","author":"EP Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez EP (2014) Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis. Steroids 91:20\u201331. https:\/\/doi.org\/10.1016\/j.steroids.2014.08.014","journal-title":"Steroids"},{"key":"4172_CR17","doi-asserted-by":"crossref","unstructured":"Reul JMHM, De Kloet ER (1985) Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology 117:2505\u20132511. doi: 0013-7227\/85\/1176-2505$02.00\/0","DOI":"10.1210\/endo-117-6-2505"},{"key":"4172_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/0306-4522(90)90244-X","volume":"39","author":"RS Ahima","year":"1990","unstructured":"Ahima RS, Harlan RE (1990) Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience 39:579\u2013604. 0306-4S22\/90$3.00+0.00","journal-title":"Neuroscience"},{"key":"4172_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s0168-0102(96)01105-4","volume":"26","author":"M Morimoto","year":"1996","unstructured":"Morimoto M, Morita N, Ozawa H, Yokoyama K, Kawata M (1996) Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study. Neurosci Res 26:235\u2013269. https:\/\/doi.org\/10.1016\/s0168-0102(96)01105-4","journal-title":"Neurosci Res"},{"key":"4172_CR20","first-page":"4","volume":"18","author":"B Dubrovsky","year":"1993","unstructured":"Dubrovsky B (1993) Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression. J Psychiatry Neurosci 18:4\u201316 PMID: 8461280","journal-title":"J Psychiatry Neurosci"},{"key":"4172_CR21","doi-asserted-by":"publisher","first-page":"109695","DOI":"10.1016\/j.biopha.2019.109695","volume":"122","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yu Y, Qiao J, Zhu L, Xiao L (2020) Mineralocorticoid receptor excessive activation involved in glucocorticoid-related brain injury. Biomed Pharmacother 122:109695. https:\/\/doi.org\/10.1016\/j.biopha.2019.109695","journal-title":"Biomed Pharmacother"},{"key":"4172_CR22","doi-asserted-by":"publisher","unstructured":"Wu TC, Chen HT, Chang HY, Yang CY, Hsiao MC, Cheng ML, Chen JC (2013) Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior. Psychoneuroendocrinology 38(6):871\u2013883. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.09.011. PMID: 23044404","DOI":"10.1016\/j.psyneuen.2012.09.011"},{"key":"4172_CR23","doi-asserted-by":"crossref","unstructured":"Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D (2012) Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 15(2):247\u2013265. doi: 10.1017\/S1461145711000368. PMID: 21375792","DOI":"10.1017\/S1461145711000368"},{"key":"4172_CR24","doi-asserted-by":"publisher","unstructured":"Gasparini S, Resch JM, Narayan SV, Peltekian L, Iverson GN, Karthik S, Geerling JC (2019) Aldosterone-sensitive HSD2 neurons in mice. Brain Struct Funct 224(1):387\u2013417. https:\/\/doi.org\/10.1007\/s00429-018-1778-y. PMID: 30343334","DOI":"10.1007\/s00429-018-1778-y"},{"key":"4172_CR25","doi-asserted-by":"publisher","unstructured":"Forstenpointner J, Maallo AMS, Elman I, Holmes S, Freeman R, Baron R, Borsook D (2022) The solitary nucleus connectivity to key autonomic regions in humans. Eur J Neurosci 56(2):3938\u20133966. https:\/\/doi.org\/10.1111\/ejn.15691. PMID: 35545280","DOI":"10.1111\/ejn.15691"},{"key":"4172_CR26","doi-asserted-by":"publisher","unstructured":"Gasparini S, Resch JM, Gore AM, Peltekian L, Geerling JC (2021) Pre-locus coeruleus neurons in rat and mouse. Am J Physiol Regul Integr Comp Physiol 320(3):R342-R361. https:\/\/doi.org\/10.1152\/ajpregu.00261.2020. PMID: 33296280","DOI":"10.1152\/ajpregu.00261.2020"},{"key":"4172_CR27","doi-asserted-by":"publisher","unstructured":"Pereira AM, Tiemensma J, Romijn JA (2010) Neuropsychiatric disorders in Cushing\u2019s syndrome. Neuroendocrinology 92Suppl1:65\u201370. https:\/\/doi.org\/10.1159\/000314317. PMID: 20829621","DOI":"10.1159\/000314317"},{"key":"4172_CR28","doi-asserted-by":"crossref","unstructured":"Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22Suppl 1:S125-132. PMID: 9264159","DOI":"10.1016\/S0306-4530(97)00021-8"},{"key":"4172_CR29","doi-asserted-by":"publisher","unstructured":"Murck H, Schlageter L, Schneider A, Adolf C, Heinrich D, Quinkler M, Beuschlein F, Reincke M, K\u00fcnzel H (2020) The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression - Lessons from primary aldosteronism. J Psychiatr Res 130:82\u201388. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.07.006. PMID: 32798773","DOI":"10.1016\/j.jpsychires.2020.07.006"},{"key":"4172_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1872214810666160809113021","volume":"10","author":"G Bernini","year":"2016","unstructured":"Bernini G, Tric\u00f2 D (2016) Cushing\u2019s syndrome and steroid dementia. Recent Pat Endocr Metab Immune Drug Discover 10:50\u201355. https:\/\/doi.org\/10.2174\/1872214810666160809113021","journal-title":"Recent Pat Endocr Metab Immune Drug Discover"},{"key":"4172_CR31","doi-asserted-by":"crossref","unstructured":"Momose KJ, Kjellberg RN, Kliman B (1971) High incidence of cortical atrophy of the cerebral and cerebellar hemispheres in Cushing\u2019s disease. Radiology 99:341\u2013348. doi: 10.1148\/99.2.341. PMID: 5553570","DOI":"10.1148\/99.2.341"},{"key":"4172_CR32","doi-asserted-by":"publisher","unstructured":"Bauduin SEEC, Nvan der Wee NJA, van der Werff SJA (2018) Structural brain abnormalities in Cushing\u2019s syndrome. Curr Opin Endocrinol Diabetes Obes 25:285\u2013289. https:\/\/doi.org\/10.1097\/MED.0000000000000414. PMID: 29746308","DOI":"10.1097\/MED.0000000000000414"},{"key":"4172_CR33","first-page":"101","volume":"12","author":"S Dogan","year":"2018","unstructured":"Dogan S, Dogan SM, Tutunculer F, Yapiciugurlar O, Genchellac H (2018) Brain atrophy and hypomyelination associated with iatrogenic Cushing syndrome in an infant. Iran J Child Neurol 12:101\u2013104 PMID: 29379569","journal-title":"Iran J Child Neurol"},{"key":"4172_CR34","doi-asserted-by":"publisher","unstructured":"Jiang H, Liu C, Pan SJ, Ren J, He NY, Sun YH, Bian LG, Yan FH, Yang WJ, Sun QF (2019) Reversible and the irreversible structural alterations on brain after resolution of hypercortisolism in Cushing\u2019s disease. Steroids 151:108457. https:\/\/doi.org\/10.1016\/j.steroids.2019.108457. PMID: 31326450","DOI":"10.1016\/j.steroids.2019.108457"},{"key":"4172_CR35","doi-asserted-by":"publisher","unstructured":"Patil CG, Lad SP, Katznelson L, Laws ER Jr (2007) Brain atrophy and cognitive deficits in Cushing\u2019s disease. Neurosurg Focus 23:E11. https:\/\/doi.org\/10.3171\/foc.2007.23.3.13. PMID: 17961025","DOI":"10.3171\/foc.2007.23.3.13"},{"key":"4172_CR36","doi-asserted-by":"publisher","unstructured":"Simmons NE, Do HM, Lipper MH, Laws ER Jr (2000) Cerebral atrophy in Cushing\u2019s disease. Surg Neurol 53:72\u201376. https:\/\/doi.org\/10.1016\/s0090-3019(99)00197-4. PMID: 10697236","DOI":"10.1016\/s0090-3019(99)00197-4"},{"key":"4172_CR37","doi-asserted-by":"publisher","unstructured":"Resmini E, Santos A, G\u00f3mez-Anson B, Vives Y, Pires P, Crespo I, Portella MJ, de Juan-Delago M, Barahona MJ, Webb MS (2012) Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97:663\u2013671. https:\/\/doi.org\/10.1210\/jc.2011-2231. PMID: 22162471","DOI":"10.1210\/jc.2011-2231"},{"key":"4172_CR38","doi-asserted-by":"publisher","unstructured":"Crespo I, Esther GM, Santos A, Valassi E, Yolanda VG, De Juan-Delago M, Webb SM, G\u00f3mez-Ans\u00f3n B, Resmini E (2014) Impaired decision-making and selective cortical frontal thinning in Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 81:826\u2013833. https:\/\/doi.org\/10.1111\/cen.12564. PMID: 25052342","DOI":"10.1111\/cen.12564"},{"key":"4172_CR39","doi-asserted-by":"publisher","unstructured":"Burkhardt T, L\u00fcdecke D, Spies L, Wittmann L, Westphal M, Flitsch J (2015) Hippocampal and cerebellar atrophy in patients with Cushing\u2019s disease. Neurosurg Focus 39:E5. https:\/\/doi.org\/10.3171\/2015.8.FOCUS15324. PMID: 26646929","DOI":"10.3171\/2015.8.FOCUS15324"},{"key":"4172_CR40","doi-asserted-by":"publisher","unstructured":"Merke DP, Giedd JN, Keil MF, Mehlinger SL, Wiggs EA, Holzer S, Rawson E, Vaituzis AC, Stratakis CA, Chrousos GP (2005) Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab 90:2531\u20132536. https:\/\/doi.org\/10.1210\/jc.2004-2488. PMID: 15741254","DOI":"10.1210\/jc.2004-2488"},{"key":"4172_CR41","doi-asserted-by":"publisher","unstructured":"Frimodt-M\u00f8ller KE, M\u00f8llegaard Jepsen JR, Feldt-Rasmussen U, Krog J (2019) Hippocampal volume, cognitive functions, depression, anxiety, and quality of life in patients with Cushing syndrome. J Clin Endocrinol Metab 104:4563\u20134577. https:\/\/doi.org\/10.1210\/jc.2019-00749. PMID: 31215997","DOI":"10.1210\/jc.2019-00749"},{"key":"4172_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14670\/HH-18-476","volume":"38","author":"JJ Miguel-Hidalgo","year":"2023","unstructured":"Miguel-Hidalgo JJ (2023) Role of stress-related glucocorticoid changes in astrocyte- oligodendrocyte interactions that regulate myelin production and maintenance. Histol Histopathol 38:1\u20138. https:\/\/doi.org\/10.14670\/HH-18-476","journal-title":"Histol Histopathol"},{"key":"4172_CR43","doi-asserted-by":"publisher","unstructured":"van der Werff SJA, Andel CD, Nienke Pannekoek J, Meijer OC, van Buchem MA, Rombouts SARB, van der Mast RC, Biermasz NR, Pereira AM, van der Wee NJA (2014) Widespread reductions of white matter integrity in patients with long-term remission of Cushing\u2019s disease. Neuroimage Clin 4:659\u2013667. https:\/\/doi.org\/10.1016\/j.nicl.2014.01.017. PMID: 24936417","DOI":"10.1016\/j.nicl.2014.01.017"},{"key":"4172_CR44","doi-asserted-by":"publisher","unstructured":"Pires P, Santos A, Vives-Gilabert Y, Webb SM, Sainz-Ruiz A, Resmini E, Crespo I, de Juan-Delago M, G\u00f3mez-Anson B (2017) White matter involvement on DTI-MRI in Cushing\u2019s syndrome relates to mood disturbances and processing speed: a case-control study. Pituitary 20:340\u2013348. https:\/\/doi.org\/10.1007\/s11102-017-0793-y. PMID: 28332051","DOI":"10.1007\/s11102-017-0793-y"},{"key":"4172_CR45","doi-asserted-by":"publisher","unstructured":"McEwen BS (2002) Cortisol, Cushing\u2019s syndrome, and a shrinking brain- new evidence for reversibility. J Clin Endocrinol Metab 87:1947\u20131948. https:\/\/doi.org\/10.1210\/jcem.87.5.9999. PMID: 11994322","DOI":"10.1210\/jcem.87.5.9999"},{"key":"4172_CR46","doi-asserted-by":"publisher","unstructured":"Ohara N, Suzuki H, Suzuki A, Kaneko M, Ishizawa M, Furukawa K, Abe T, Matsubayashi Y, Yamada T, Hanyu O, Shimohata T, Sone T (2014) H Reversible brain atrophy and cognitive impairment in an adolescent Japanese patient with primary adrenal Cushing\u2019s syndrome. Neuropsychiatr Dis Treat 10:1763\u20131767. https:\/\/doi.org\/10.2147\/NDT.S70611. PMID: 25246796","DOI":"10.2147\/NDT.S70611"},{"key":"4172_CR47","doi-asserted-by":"publisher","unstructured":"Tirosh I, RaviPrakash H, Papadakis GZ, Tatsi C, Belyavskaya E, Charalampos L, Lodish MB, Bagci U, Stratakis CA (2010) Computerized analysis of brain MRI parameter dynamics in young patients with Cushing syndrome-a case-control study. J Clin Endocrinol Metab 105:e2069-2077. https:\/\/doi.org\/10.1210\/clinem\/dgz303. PMID: 31875913","DOI":"10.1210\/clinem\/dgz303"},{"key":"4172_CR48","doi-asserted-by":"publisher","unstructured":"Jiang H, Ren J, He NY, Liu C, Sun YH, Jian FF, Bian LG, Shen JK, Yan FH, Pan SJ, Sun QF (2017) Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing\u2019s disease. Clin Endocrinol (Oxf) 87:367\u2013374. https:\/\/doi.org\/10.1111\/cen.13381. PMID: 28543178","DOI":"10.1111\/cen.13381"},{"key":"4172_CR49","doi-asserted-by":"publisher","unstructured":"Santos A, Resmini E, Crespo I, Pires P, Vives-Gilabert Y, Granell E, Valassi E, G\u00f3mez-Anson B, Mart\u00ednez-Mombl\u00e1n MA, Matar\u00f3 M, Webb SM (2014) Small cerebellar cortex volume in patients with active Cushing\u2019s syndrome. Eur J Endocrinol 171:461\u2013469. https:\/\/doi.org\/10.1530\/EJE-14-0371. PMID: 25005936","DOI":"10.1530\/EJE-14-0371"},{"key":"4172_CR50","doi-asserted-by":"publisher","unstructured":"Santos A, Granell E, G\u00f3mez-Ans\u00f3n B, Crespo I, Pires P, Vives-Gilabert Y, Valassi E, Webb SM, Resmini E (2017) Depression and anxiety scores are associated with amygdala volume in Cushing\u2019s syndrome: preliminary study. Biomed Res Int 2017:2061935. https:\/\/doi.org\/10.1155\/2017\/2061935. PMID: 28607927","DOI":"10.1155\/2017\/2061935"},{"key":"4172_CR51","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhang J, Tan H, Li J, Yu Y (2020) Detrimental effects of hypercortisolism on brain structure and related risk factors. Sci Rep 10:12708. https:\/\/doi.org\/10.1038\/s41598-020-68166-0. PMID: 32728036","DOI":"10.1038\/s41598-020-68166-0"},{"key":"4172_CR52","doi-asserted-by":"publisher","unstructured":"Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing\u2019s disease. Biol Psychiatry 1999;46:1595\u20131602. https:\/\/doi.org\/10.1016\/s0006-3223(99)00203-6. PMID: 10624540","DOI":"10.1016\/s0006-3223(99)00203-6"},{"key":"4172_CR53","doi-asserted-by":"publisher","unstructured":"Andela CD, van der Werff SJ, Pannekoek JN, van den Berg SM, Meijer OC, Buchem MA, Rombouts SA, van der Mast RC, Romijn JA, Tiemensma J, Biermasz NR, van der Wee NJ, Pereira AM (2013) Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing\u2019s disease: a case-control study. Eur J Endocrinol 169:811\u2013819. https:\/\/doi.org\/10.1530\/EJE-13-0471. PMID: 24031092","DOI":"10.1530\/EJE-13-0471"},{"key":"4172_CR54","doi-asserted-by":"publisher","unstructured":"Bourdeau I, Bard C, No\u00ebl B, Leclerc I, Cordeau MP, B\u00e9lair M, Lesage J, Lafontaine L, Lacroix A (2002) Loss of brain volume in endogenous Cushing\u2019s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87:1949\u20131954. https:\/\/doi.org\/10.1210\/jcem.87.5.8493. PMID: 11994323","DOI":"10.1210\/jcem.87.5.8493"},{"key":"4172_CR55","doi-asserted-by":"publisher","unstructured":"Heinz ER, Martinez J, Haenggeli A (1977) Reversibility of cerebral atrophy in anorexia nervosa and Cushing\u2019s syndrome. J Comput Assist Tomogr 1:415\u2013418. https:\/\/doi.org\/10.1097\/00004728-197710000-00006. PMID: 615219","DOI":"10.1097\/00004728-197710000-00006"},{"key":"4172_CR56","doi-asserted-by":"publisher","unstructured":"Resmini E, Santos A, G\u00f3mez-Anson B, L\u00f3pez-Mourelo O, Pires P, Vives-Gilabert Y, Crespo I, Portella MJ, de Juan-Delago M, Webb SM (2013) Hippocampal dysfunction in cured Cushing\u2019s syndrome patients, detected by (1) H-MR-spectroscopy. Clin Endocrinol (Oxf) 79:700\u2013707. https:\/\/doi.org\/10.1111\/cen.12224. PMID: 23594250","DOI":"10.1111\/cen.12224"},{"key":"4172_CR57","doi-asserted-by":"publisher","unstructured":"Brown ES, Woolston DJ, Frol AB (2008) Amygdala volume in patients receiving chronic corticosteroid therapy. Biol Psychiatry 63:705\u2013709. https:\/\/doi.org\/10.1016\/j.biopsych.2007.09.014. PMID: 17981265","DOI":"10.1016\/j.biopsych.2007.09.014"},{"key":"4172_CR58","doi-asserted-by":"publisher","unstructured":"Spiegel W, McGeady SJ, Mansmann HC Jr (1992) Cerebral cortical atrophy and central nervous system (CNS) symptoms in a steroid-treated child with asthma. J Allergy Clin Immunol 89:918\u2013919. https:\/\/doi.org\/10.1016\/0091-6749(92)90449-c. PMID: 1560173","DOI":"10.1016\/0091-6749(92)90449-c"},{"key":"4172_CR59","doi-asserted-by":"publisher","unstructured":"Brown ES, Jeon-Slaughter H, Lu H, Jamadar R, Issac S, Shad M, Denniston D, Tamminga C, Nakamura A, Thomas BP (2015) Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone. Neuropsychopharmacology 40:1216\u20131221. https:\/\/doi.org\/10.1038\/npp.2014.307. PMID: 25409592","DOI":"10.1038\/npp.2014.307"},{"key":"4172_CR60","doi-asserted-by":"publisher","unstructured":"Tessner KD, Walker EF, Dhruv SH, Hochman K, Hamann S (2007) The relation of cortisol levels with hippocampus volumes under baseline and challenge conditions. Brain Res 1179;70\u201378. https:\/\/doi.org\/10.1016\/j.brainres.2007.05.027. PMID: 17936736","DOI":"10.1016\/j.brainres.2007.05.027"},{"key":"4172_CR61","doi-asserted-by":"publisher","unstructured":"Nishiyama M, Iwasaki Y, Makino S (2022) Animal models of Cushing\u2019s syndrome. Endocrinology 163:bqac173. https:\/\/doi.org\/10.1210\/endocr\/bqac173. PMID: 36240318","DOI":"10.1210\/endocr\/bqac173"},{"key":"4172_CR62","doi-asserted-by":"publisher","unstructured":"Sahut-Barnola I, de Joussineau C, Val P, Lambert-Langlais S, Damon C, Lefran\u00e7ois-Martinez AM, Pointud JC, Marceau G, Sapin V, Tissier F, Ragazzon B, Bertherat Kirschner LS, Stratakis CA, Martinez A (2010) Cushing\u2019s syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet 6:e1000980. https:\/\/doi.org\/10.1371\/journal.pgen.1000980. PMID: 20548949","DOI":"10.1371\/journal.pgen.1000980"},{"key":"4172_CR63","doi-asserted-by":"publisher","unstructured":"Amaya JM, Suidgeest E, Sahut-Barnola I, Dumontet T, Montanier N, Pag\u00e8s G, Keller C, van der Weerd L, Pereira AM, Martinez A, Meijer OC (2021) Effects of long-term endogenous corticosteroid exposure on brain volume and glial cells in the AdKO mouse. Front Neurosci 15:604103. https:\/\/doi.org\/10.3389\/fnins.2021.604103. PMID: 33642975","DOI":"10.3389\/fnins.2021.604103"},{"key":"4172_CR64","doi-asserted-by":"publisher","unstructured":"Amaya JM, Viho EMG, Sips HCM, Lalai RA, Sahut-Barnola I, Dumontet T, Montanier N, Pereira AM, Martinez A, Meijer OC (2022) Gene expression changes in the brain of a Cushing\u2019s syndrome mouse model. J Neuroendocrinol 34:e13125. https:\/\/doi.org\/10.1111\/jne.13125. PMID: 35365898","DOI":"10.1111\/jne.13125"},{"key":"4172_CR65","doi-asserted-by":"publisher","unstructured":"Nakayama S, Nishiyama M, Iwasaki Y, Shinahara M, Okada Y, Tsuda M, Okazaki M, Tsugita M, Taguchi T, Makino S, Stenzel-Poore MP, Hashimoto K, Terada Y (2011) Corticotropin-releasing hormone (CRH) transgenic mice display hyperphagia with increased Agouti-related protein mRNA in the hypothalamic arcuate nucleus. Endocr J 58:279\u2013286. https:\/\/doi.org\/10.1507\/endocrj.k10e-370. PMID: 21389639","DOI":"10.1507\/endocrj.k10e-370"},{"key":"4172_CR66","doi-asserted-by":"publisher","unstructured":"Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W (1992) Development of Cushing\u2019s syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130:3378\u20133386. https:\/\/doi.org\/10.1210\/endo.130.6.1597149. PMID: 1597149","DOI":"10.1210\/endo.130.6.1597149"},{"key":"4172_CR67","doi-asserted-by":"crossref","unstructured":"Goebel M, Fleming SM, Million M, Stengel A, Tach\u00e9 Y, Wang L (2010) Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctions. Neurosci Lett 473:11\u201315. doi: 10.1016\/j.neulet.2010.01.068. PMID: 20132869","DOI":"10.1016\/j.neulet.2010.01.068"},{"key":"4172_CR68","doi-asserted-by":"publisher","unstructured":"Wellman DL (2001) Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol 49:245\u2013253. https:\/\/doi.org\/10.1002\/neu.1079. PMID: 11745662","DOI":"10.1002\/neu.1079"},{"key":"4172_CR69","doi-asserted-by":"publisher","unstructured":"Cerqueira JJ, Catania C, Sotiropoulos I, Schubert M, Kalisch R, Almeida OF, Auer DP, Sousa N (2005) Corticosteroid status influences the volume of the rat cingulate cortex- a magnetic resonance imaging study. J Psychiatr Res 39:451\u2013460. https:\/\/doi.org\/10.1016\/j.jpsychires.2005.01.003. PMID: 15992553","DOI":"10.1016\/j.jpsychires.2005.01.003"},{"key":"4172_CR70","doi-asserted-by":"publisher","unstructured":"Bisagno V, Ferrini M, R\u00edos H, Zieher LM, Wikinski SI (2000) Chronic corticosterone impairs inhibitory avoidance in rats: possible link with atrophy of hippocampal CA3 neurons. Pharmacol Biochem Behav 66:235\u2013240. https:\/\/doi.org\/10.1016\/s0091-3057(00)00265-3. PMID: 10880674","DOI":"10.1016\/s0091-3057(00)00265-3"},{"key":"4172_CR71","doi-asserted-by":"publisher","unstructured":"Woolley CS, Gould E, McEwen BS (1990) Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res 531:225\u2013231. https:\/\/doi.org\/10.1016\/0006-8993(90)90778-a. PMID: 1705153","DOI":"10.1016\/0006-8993(90)90778-a"},{"key":"4172_CR72","doi-asserted-by":"publisher","unstructured":"Magari\u00f1os AM, Orchinik M, McEwen BS (1998) Morphological changes in the hippocampal CA3 region induced by non-invasive glucocorticoid administration: a paradox. Brain Res 809:314\u2013318. https:\/\/doi.org\/10.1016\/s0006-8993(98)00882-8. PMID: 9853126","DOI":"10.1016\/s0006-8993(98)00882-8"},{"key":"4172_CR73","doi-asserted-by":"publisher","unstructured":"Scheff SW, Benardo LS, Cotman SW (1980) Hydrocortison administration retards axon sprouting in the rat dentate gyrus. Exp Neurol 68:195\u2013201. https:\/\/doi.org\/10.1016\/0014-4886(80)90077-1. PMID: 7363986","DOI":"10.1016\/0014-4886(80)90077-1"},{"key":"4172_CR74","doi-asserted-by":"publisher","unstructured":"Scheff SW, Cotman CW (1982) Chronic glucocorticoid therapy alters axon sprouting in the hippocampal dentate gyrus. Exp Neurol 76:644\u2013654. https:\/\/doi.org\/10.1016\/0014-4886(82)90131-5. PMID: 7084379","DOI":"10.1016\/0014-4886(82)90131-5"},{"key":"4172_CR75","doi-asserted-by":"publisher","unstructured":"Scheff SW, Hoff SF, Anderson KJ (1986) Altered regulation of lesion-induced synaptogenesis by adrenalectomy and corticosterone in young adult rats. Exp Neurol 93:456\u2013470. https:\/\/doi.org\/10.1016\/0014-4886(86)90167-6. PMID: 3743694","DOI":"10.1016\/0014-4886(86)90167-6"},{"key":"4172_CR76","doi-asserted-by":"publisher","unstructured":"Hashimoto H, Marystone JF, Greenough WT, Bohn MC (1989) Neonatal adrenalectomy alters dendritic branching of hippocampal granule cells. Exp Neurol 104:62\u201367. https:\/\/doi.org\/10.1016\/0014-4886(89)90009-5. PMID: 2924871","DOI":"10.1016\/0014-4886(89)90009-5"},{"key":"4172_CR77","doi-asserted-by":"publisher","unstructured":"Mitra R, Sapolsky RM (2008) Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc Natl Acad Sci USA 105:5573\u20135578. https:\/\/doi.org\/10.1073\/pnas.0705615105. PMID: 18391224","DOI":"10.1073\/pnas.0705615105"},{"key":"4172_CR78","doi-asserted-by":"publisher","unstructured":"Sapolsky RM, Krey LC, McEwen BS (1985) Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 5:1222\u20131227. https:\/\/doi.org\/10.1523\/JNEUROSCI.05-05-01222.1985. PMID: 3998818","DOI":"10.1523\/JNEUROSCI.05-05-01222.1985"},{"key":"4172_CR79","doi-asserted-by":"publisher","unstructured":"Sapolsky RM, Uno H, Rebert CS, Finch CE (1990) Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 10:2897\u20132902. https:\/\/doi.org\/10.1523\/JNEUROSCI.10-09-02897.1990. PMID: 2398367","DOI":"10.1523\/JNEUROSCI.10-09-02897.1990"},{"key":"4172_CR80","doi-asserted-by":"publisher","unstructured":"Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Grabber JE, Raskind MA, Peskind ER (1999) Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. J Neurosci 19:2356\u20132361. https:\/\/doi.org\/10.1523\/JNEUROSCI.19-06-02356.1999. PMID: 10066285","DOI":"10.1523\/JNEUROSCI.19-06-02356"},{"key":"4172_CR81","doi-asserted-by":"publisher","unstructured":"Bodnoff SR, Humphreys AG, Lehman JC, Diamond DM, Rose GM, Meaney MJ (1995) Enduring effects of chronic corticosterone treatment on spatial learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. J Neurosci 15:61\u201369. https:\/\/doi.org\/10.1523\/JNEUROSCI.15-01-00061.1995. PMID: 7823152","DOI":"10.1523\/JNEUROSCI.15-01-00061"},{"key":"4172_CR82","doi-asserted-by":"publisher","unstructured":"Gould E, Woolley CS, McEwen BS (1991) Adrenal steroids regulate postnatal development of the rat dentate gyrus: I. Effects of glucocorticoids on cell death. J Comp Neurol 313:479\u2013485. https:\/\/doi.org\/10.1002\/cne.903130308. PMID: 1770171","DOI":"10.1002\/cne.903130308"},{"key":"4172_CR83","doi-asserted-by":"publisher","unstructured":"Gould E, Woolley CS, Cameron HA, Daniels DC, McEwen BS (1991) Adrenal steroids regulate postnatal development of the rat dentate gyrus: II. Effects of glucocorticoids and mineralocorticoids on cell birth. J Comp Neurol 313:486\u2013493. https:\/\/doi.org\/10.1002\/cne.903130309. PMID: 1770172","DOI":"10.1002\/cne.903130309"},{"key":"4172_CR84","doi-asserted-by":"publisher","unstructured":"Sousa N, Madeira MD, Paula-Barbosa MM (1998) Effects of corticosterone treatment and rehabilitation on the hippocampal formation of neonatal and adult rats: an unbiased stereological study. Brain Res 794:199\u2013210. https:\/\/doi.org\/10.1016\/s0006-8993(98)00218-2. PMID: 9622630","DOI":"10.1016\/s0006-8993(98)00218-2"},{"key":"4172_CR85","doi-asserted-by":"publisher","unstructured":"Bohn MC (1980) Granule cell genesis in the hippocampus of rats treated neonatally with hydrocortisone. Neuroscience 5:2003\u20132012. https:\/\/doi.org\/10.1016\/0306-4522(80)90045-7. PMID: 7432634","DOI":"10.1016\/0306-4522(80)90045-7"},{"key":"4172_CR86","doi-asserted-by":"publisher","unstructured":"Howard E (1965) Effects of corticosterone and food restriction on DNA, RNA and cholesterol contents of the brain and liver in infant mice. J Neurochem 12:181\u2013191. https:\/\/doi.org\/10.1111\/j.1471-4159.1965.tb06754.x. PMID: 14272655","DOI":"10.1111\/j.1471-4159.1965.tb06754.x"},{"key":"4172_CR87","doi-asserted-by":"publisher","unstructured":"Howard E (1968) Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol 22:191\u2013208. https:\/\/doi.org\/10.1016\/0014-4886(68)90051-4. PMID: 5724943","DOI":"10.1016\/0014-4886(68)90051-4"},{"key":"4172_CR88","doi-asserted-by":"publisher","unstructured":"Bohn MC, Lauder JM (1980) Cerebellar granule cell genesis in the hydrocortisone-treated rats. Dev Neurosci 3:81\u201389. https:\/\/doi.org\/10.1159\/000112380. PMID: 7418632","DOI":"10.1159\/000112380"},{"key":"4172_CR89","doi-asserted-by":"publisher","unstructured":"Cotterrell M, Bal\u00e1zs R, Johnson AL (1972) Effects of corticosteroids on the biochemical maturation of rat brain: postnatal cell formation. J Neurochem 19:2151\u20132167. https:\/\/doi.org\/10.1111\/j.1471-4159.1972.tb05124.x. PMID: 5072390","DOI":"10.1111\/j.1471-4159.1972.tb05124.x"},{"key":"4172_CR90","doi-asserted-by":"publisher","unstructured":"Busceti CL, Bucci D, Scioli M, Di Pietro P, Nicoletti F, Puglisi-Allegra S, Ferrucci M, Fornai F (2022) Chronic treatment with corticosterone increases the number of tyrosine hydroxylase-expressing cells within specific nuclei of the brainstem reticular formation. Front Neuroanat 16:976714. https:\/\/doi.org\/10.3389\/fnana.2022.976714. PMID: 36387998","DOI":"10.3389\/fnana.2022.976714"},{"key":"4172_CR91","doi-asserted-by":"publisher","unstructured":"Papakokkinou E, Ragnarsson O (2023) Functional brain alterations in Cushing\u2019s syndrome. Front Endocrinol (Lausanne) 14:1163482. https:\/\/doi.org\/10.3389\/fendo.2023.1163482. PMID: 37152946","DOI":"10.3389\/fendo.2023.1163482"},{"key":"4172_CR92","first-page":"786","volume":"39","author":"CL Brunetti","year":"1998","unstructured":"Brunetti CL, Fulham MJ, Aloj L, De Souza B, Nieman L, Oldfield EH, Di Chiro G (1998) Decreased brain glucose utilization in patients with Cushing\u2019s disease. J Nucl Med 39:786\u2013790 PMID: 9591575","journal-title":"J Nucl Med"},{"key":"4172_CR93","doi-asserted-by":"publisher","unstructured":"Liu S, Wang Y, Xu K, Ping F, Li F, Wang R, Cheng X (2017) Voxel-based comparison of brain glucose metabolism between patients with Cushing\u2019s disease and healthy subjects. Neuroimage Clin 17:354\u2013358. https:\/\/doi.org\/10.1016\/j.nicl.2017.10.038. PMID: 29159047","DOI":"10.1016\/j.nicl.2017.10.038"},{"key":"4172_CR94","doi-asserted-by":"publisher","unstructured":"Liu S, Wang Y, Xu K, Ping F, Wang R, Li F, Cheng X (2016) Brain glucose metabolism is associated with hormone level in Cushing\u2019s disease: a voxel-based study using FDG-PET. Neuroimage Clin 12:415\u2013419. https:\/\/doi.org\/10.1016\/j.nicl.2016.08.018. PMID: 27622138","DOI":"10.1016\/j.nicl.2016.08.018"},{"key":"4172_CR95","doi-asserted-by":"publisher","unstructured":"Horner HC, Packan DR, Sapolsky RM (1990) Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology 52:57\u201364. https:\/\/doi.org\/10.1159\/000125539. PMID: 2118608","DOI":"10.1159\/000125539"},{"key":"4172_CR96","doi-asserted-by":"publisher","unstructured":"Virgin CE, Jr, Ha TP, Packan DR, Tombaugh GC, Yang SH, Horner HC, Sapolsky RM (1991) Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. J Neurochem 57:1422\u20131428. https:\/\/doi.org\/10.1111\/j.1471-4159.1991.tb08309.x. PMID: 1680166","DOI":"10.1111\/j.1471-4159.1991.tb08309.x"},{"key":"4172_CR97","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0165-3806(87)90197-0","volume":"431","author":"RA Warringa","year":"1987","unstructured":"Warringa RA, Hoeben RC, Koper JW, Sykes JE, van Golde LM, Lopes-Cardozo M (1987) Hydrocortisone stimulates the development of oligodendrocytes in primary glial cultures and affects glucose metabolism and lipid synthesis in these cultures. Brain Res 431:79\u201386 PMID: 3040187","journal-title":"Brain Res"},{"key":"4172_CR98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0079-6123(04)48029-7","volume":"148","author":"JE Slemmer","year":"2005","unstructured":"Slemmer JE, De Zeeuw CI, Weber JT (2005) Don\u2019t get too excited: mechanisms of glutamate-mediated Purkinje cell death. Rev Prog Brain Res 148:367\u2013390. https:\/\/doi.org\/10.1016\/S0079-6123(04)48029-7","journal-title":"Rev Prog Brain Res"},{"key":"4172_CR99","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.biopsych.2004.09.003","volume":"56","author":"C Grillon","year":"2004","unstructured":"Grillon C, Smith K, Haynos A, Nieman LK (2004) Deficits in hippocampus-mediated pavlovian conditioning in endogenous hypercortisolism. Biol Psychiatry 56:837\u2013843. https:\/\/doi.org\/10.1016\/j.biopsych.2004.09.003","journal-title":"Biol Psychiatry"},{"issue":"6","key":"4172_CR100","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.mehy.2012.08.027","volume":"79","author":"DJ Schutter","year":"2012","unstructured":"Schutter DJ (2012) The cerebello-hypothalamic-pituitary-adrenal axis dysregulation hypothesis in depressive disorder. Med Hypotheses 79(6):779\u2013783. https:\/\/doi.org\/10.1016\/j.mehy.2012.08.027","journal-title":"Med Hypotheses"},{"key":"4172_CR101","doi-asserted-by":"publisher","unstructured":"Kadekaro M, Ito M, Gross PM (1988) Local cerebral glucose utilization is increased in acutely adrenalectomized rats. Neuroendocrinology 47:329\u2013334. https:\/\/doi.org\/10.1159\/000124933. PMID: 3374757","DOI":"10.1159\/000124933"},{"key":"4172_CR102","doi-asserted-by":"publisher","unstructured":"Lu J, Montgomery BK, Chatain GP, Bugarini A, Zhang Q, Wang X, Edwards NA, Ray-Chaudhury A, Merrill MJ, Lonser RR, Chittiboina P (2018) Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1. Mol Cell Endocrinol 470:105\u2013114. https:\/\/doi.org\/10.1016\/j.mce.2017.10.003. PMID: 28986303","DOI":"10.1016\/j.mce.2017.10.003"},{"key":"4172_CR103","doi-asserted-by":"publisher","unstructured":"Cheng H, Gao L, Hou B, Feng F, Guo X, Wang Z, Feng M, Xing B, Fan Y (2020) Reversibility of cerebral blood flow in patients with Cushing\u2019s disease after surgery treatment. Metabolism 104:154050. https:\/\/doi.org\/10.1016\/j.metabol.2019.154050. PMID: 31863780","DOI":"10.1016\/j.metabol.2019.154050"},{"key":"4172_CR104","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhou T, Feng S, Wang W, Liu H, Wang P, Sha Z, Yu X (2021) The chronic effect of cortisol on orchestrating cerebral blood flow and brain functional connectivity: evidence from Cushing\u2019s disease. Metabolism 115:154432. https:\/\/doi.org\/10.1016\/j.metabol.2020.154432. PMID: 33197455","DOI":"10.1016\/j.metabol.2020.154432"},{"key":"4172_CR105","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/cns.12835","volume":"24","author":"FF Zhang","year":"2018","unstructured":"Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY (2018) Brain structure alterations in depression: psychoradiological evidence. Neurosci Ther 24:994\u20131003. https:\/\/doi.org\/10.1111\/cns.12835","journal-title":"Neurosci Ther"},{"key":"4172_CR106","doi-asserted-by":"publisher","unstructured":"Wang X, Zhou T, Wang P, Zhang L, Feng S, Meng X, Yu Y, Zhang Y (2019) Dysregulation of resting-state functional connectivity in patients with Cushing\u2019s disease. Neuroradiology 61:911\u2013920. https:\/\/doi.org\/10.1007\/s00234-019-02223-y. PMID: 31101946","DOI":"10.1007\/s00234-019-02223-y"},{"key":"4172_CR107","doi-asserted-by":"publisher","unstructured":"Stomby A, Salami A, Dahlqvist P, Evang JA, Ryberg M, Bollerslev J, Olsson T, Johannsson G, Ragnarsson O (2019) Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing\u2019s syndrome in remission. Eur J Endocrinol 180:329\u2013338. https:\/\/doi.org\/10.1530\/EJE-19-0028. PMID: 30939453","DOI":"10.1530\/EJE-19-0028"},{"key":"4172_CR108","doi-asserted-by":"publisher","unstructured":"van der Werff SJ, Pannekoek JN, Andela CD, Meijer OC, van Buchem MA, Rombouts SA, van der Mast RC, Biermasz NR, Pereira AM, van der Wee NJ (2015) Resting-state functional connectivity in patients with long-term remission of Cushing\u2019s disease. Neuropsychopharmacology 40:1888\u20131898. https:\/\/doi.org\/10.1038\/npp.2015.38. PMID: 25652248","DOI":"10.1038\/npp.2015.38"},{"key":"4172_CR109","doi-asserted-by":"publisher","unstructured":"Jiang H, He NY, Sun YH, Jian FF, Bian LG, Shen JK, Yan FH, Pan SJ, Sun QF (2017) Altered spontaneous brain activity in Cushing\u2019s disease: a resting-state functional MRI study. Clin. Endocrinol (Oxf) 86:367\u2013376. https:\/\/doi.org\/10.1111\/cen.13277. PMID: 27859451","DOI":"10.1111\/cen.13277"},{"key":"4172_CR110","doi-asserted-by":"publisher","unstructured":"Ernst M, Maheu FS, Schroth E, Hardin J, Golan LG, Cameron J, Allen R, Holzer S, Nelson E, Pine DS, Merke DP (2007) Amygdala function in adolescents with congenital adrenal hyperplasia: a model for the study of early steroid abnormalities. Neuropsychologia 45:2104\u20132113. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2007.01.019. PMID: 17336344","DOI":"10.1016\/j.neuropsychologia.2007.01.019"},{"key":"4172_CR111","doi-asserted-by":"crossref","unstructured":"Maheu FS, Mazzone L, Merke DP, Keil MF, Stratakis CA, Pine DS, Ernst M (2008) Altered amygdala and hippocampus function in adolescents with hypercortisolemia: a functional magnetic resonance imaging study of Cushing syndrome. Dev Psychopathol 20:1177\u20131189. doi: 10.1017\/S0954579408000564. PMID: 18838037","DOI":"10.1017\/S0954579408000564"},{"key":"4172_CR112","doi-asserted-by":"publisher","unstructured":"Langenecker SA, Weisenbach SL, Giordani B, Brice\u00f1o EM, Guidotti Breting LM, Schallmo MP, Leon HM, Noll DC, Zubieta JK, Schteingart DE, Starkman MN (2012) Impact of chronic hypercortisolemia on affective processing. Neuropharmacology 62:217\u2013225. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.07.006. PMID: 21787793","DOI":"10.1016\/j.neuropharm.2011.07.006"},{"key":"4172_CR113","doi-asserted-by":"publisher","unstructured":"Ragnarsson O, Stomby A, Dahlqvist P, Evang JA, Ryberg M, Olsson T, Bollerslev J, Nyberg L, Johannsson G (2017) Decreased prefrontal functional brain response during memory testing in women with Cushing\u2019s syndrome in remission. Psychoneuroendocrinology 82:117\u2013125. https:\/\/doi.org\/10.1016\/j.psyneuen.2017.05.010. PMID: 28544904","DOI":"10.1016\/j.psyneuen.2017.05.010"},{"key":"4172_CR114","doi-asserted-by":"publisher","unstructured":"Bas-Hoogendam JM, Andela CD, van der Werff SJ, Pannekoek JN, van Steenbergen H, Meijer OC, van Buchem MA, Rombouts SA, van der Mast RC, Biermasz NR, van der Wee NJ, Pereira AM (2015) Altered neural processing of emotional faces in remitted Cushing\u2019s disease. Psychoneuroendocrinology 59:134\u2013146. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.05.001. PMID: 26092780","DOI":"10.1016\/j.psyneuen.2015.05.001"},{"key":"4172_CR115","doi-asserted-by":"publisher","unstructured":"Wong-Riley MT (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 12:94\u2013101. https:\/\/doi.org\/10.1016\/0166-2236(89)90165-3. PMID: 2469224","DOI":"10.1016\/0166-2236(89)90165-3"},{"key":"4172_CR116","doi-asserted-by":"publisher","unstructured":"Bennett MC, Mlady GW, Fleshner M, Rose GM (1996) Synergy between chronic corticosterone and sodium azide treatments in producing a spatial learning deficit and inhibiting cytochrome oxidase activity. Proc Natl Acad Sci USA 93:1330\u20131334. https:\/\/doi.org\/10.1073\/pnas.93.3.1330. PMID: 8577764","DOI":"10.1073\/pnas.93.3.1330"},{"key":"4172_CR117","doi-asserted-by":"publisher","unstructured":"Harl\u00e9 G, Lalonde R, Fonte C, Ropars A, Frippiat JP, Strazielle C (2017) Repeated corticosterone injections in adult mice alter stress hormonal receptor expression in the cerebellum and motor coordination without affecting spatial learning. Behav. Brain Res 326:121\u2013131. https:\/\/doi.org\/10.1016\/j.bbr.2017.02.035. PMID: 28263830","DOI":"10.1016\/j.bbr.2017.02.035"},{"key":"4172_CR118","doi-asserted-by":"publisher","unstructured":"Khiat A, Bard C, Lacroix A, Rousseau J, Boulanger Y (1999) Brain metabolic alterations in Cushing\u2019s syndrome as monitored by proton magnetic resonance spectroscopy. NMR Biomed 12:357\u2013363. https:\/\/doi.org\/10.1002\/(sici)1099-1492(199910)12:6%3C357::aid-nbm584%3E3.0.co;2-u. PMID: 10516617","DOI":"10.1002\/(sici)1099-1492(199910)12:6%3C357::aid-nbm584%3E3.0.co;2-u"},{"key":"4172_CR119","doi-asserted-by":"publisher","unstructured":"Khiat A, Bard C, Lacroix A, Boulanger Y (2000) Long recovery of the brain choline level in treated Cushing\u2019s patients as monitored by proton magnetic resonance spectroscopy. Brain Res 862:301\u2013307. https:\/\/doi.org\/10.1016\/s0006-8993(00)02147-8. PMID: 10799704","DOI":"10.1016\/s0006-8993(00)02147-8"},{"key":"4172_CR120","doi-asserted-by":"publisher","unstructured":"Khiat A, Yared Z, Bard C, Lacroix A, Boulanger Y (2001) Long-term brain metabolic alterations in exogenous Cushing\u2019s syndrome as monitored by proton magnetic resonance spectroscopy. Brain Res 911:134\u2013140. https:\/\/doi.org\/10.1016\/s0006-8993(01)02697-x. PMID: 11511380","DOI":"10.1016\/s0006-8993(01)02697-x"},{"key":"4172_CR121","doi-asserted-by":"publisher","unstructured":"Burrows AW, Burke CW, Rees LH (1977) Cyproheptadine and Cushing\u2019s disease. Br Med J 1:1084. https:\/\/doi.org\/10.1136\/bmj.1.6068.1084. PMID: 858057","DOI":"10.1136\/bmj.1.6068.1084"},{"key":"4172_CR122","doi-asserted-by":"publisher","unstructured":"Jimenez-Alonso J, Munoz-Avila J, Jaimez L, P\u00e9rez-Jimenez F, Bellido C, Jim\u00e9nez-Perep\u00e9rez JA (1982) Cyproheptadine-induced remission of Cushing\u2019s disease due to pituitary basophil adenoma. Drug Intell Clin Pharm 16:962\u2013965. https:\/\/doi.org\/10.1177\/106002808201601213. PMID: 6295736","DOI":"10.1177\/106002808201601213"},{"key":"4172_CR123","doi-asserted-by":"publisher","unstructured":"Lankford HV, Tucker HS, Blackard WG (1981) A cyproheptadine-reversible defect in ACTH control persisting after removal of the pituitary tumor in Cushing\u2019s disease. N Engl J Med 305:1244\u20131248. https:\/\/doi.org\/10.1056\/NEJM198111193052103. PMID: 6270557","DOI":"10.1056\/NEJM198111193052103"},{"key":"4172_CR124","doi-asserted-by":"publisher","unstructured":"Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 25:661\u2013667. https:\/\/doi.org\/10.1111\/j.1365-2265.1986.tb03621.x. PMID: 3115630","DOI":"10.1111\/j.1365-2265.1986.tb03621.x"},{"key":"4172_CR125","doi-asserted-by":"publisher","unstructured":"Tanakol R, Alag\u00f6l F, Azizlerli H, Sandalci O, Terzio\u011flu T, Berker F (1996) Cyproheptadine treatment in Cushing\u2019s disease. J Endocrinol Invest 19:242\u2013247. https:\/\/doi.org\/10.1007\/BF03349875. PMID: 8862505","DOI":"10.1007\/BF03349875"},{"key":"4172_CR126","doi-asserted-by":"publisher","unstructured":"Couch RM, Smail PJ, Dean HJ, Winter JS (1984) Prolonged remission of Cushing disease after treatment with cyproheptadine. J Pediatr 104:906\u2013908. https:\/\/doi.org\/10.1016\/s0022-3476(84)80495-3. PMID: 6327962","DOI":"10.1016\/s0022-3476(84)80495-3"},{"key":"4172_CR127","doi-asserted-by":"publisher","unstructured":"D\u2019Ercole AJ, Morris MA, Underwood LE, Van Wyk JJ, Feldman JM (1977) Treatment of Cushing disease in childhood with cyproheptadine. J Pediatr 90:834\u2013835. https:\/\/doi.org\/10.1016\/s0022-3476(77)81265-1. PMID: 853345","DOI":"10.1016\/s0022-3476(77)81265-1"},{"key":"4172_CR128","doi-asserted-by":"publisher","unstructured":"Krieger DT, Amorosa L, Linick F (1975) Cyproheptadine-induced remission of Cushing\u2019s disease. N Engl J Med 293:893\u2013896. https:\/\/doi.org\/10.1056\/NEJM197510302931802. PMID: 1177986","DOI":"10.1056\/NEJM197510302931802"},{"key":"4172_CR129","doi-asserted-by":"publisher","unstructured":"Tucci JR, Nowakowski KJ, Jackson IM (1989) Cyproheptadine may act at the pituitary in Cushing\u2019s disease: evidence from CRF stimulation. J Endocrinol Invest 12:197\u2013200. https:\/\/doi.org\/10.1007\/BF03349961. PMID: 2542391","DOI":"10.1007\/BF03349961"},{"key":"4172_CR130","doi-asserted-by":"publisher","unstructured":"Wiesen M, Ross F, Krieger DT (1983) Prolonged remission of a case of Cushing\u2019s disease following cessation of cyproheptadine therapy. Acta Endocrinol (Copenh) 102:436\u2013438. https:\/\/doi.org\/10.1530\/acta.0.1020436. PMID: 6829265","DOI":"10.1530\/acta.0.1020436"},{"key":"4172_CR131","doi-asserted-by":"publisher","unstructured":"Barnes P, Shaw K, Ross E (1977) Cushing\u2019s disease: Successful treatment with cyproheptadine. Lancet May28:1148-9. https:\/\/doi.org\/10.1016\/s0140-6736(77)92402-3. PMID: 68240","DOI":"10.1016\/s0140-6736(77)92402-3"},{"key":"4172_CR132","doi-asserted-by":"publisher","unstructured":"Marek J, Matys Z, Gregorov\u00e1 I (1977) Cyproheptadine in Cushing\u2019s syndrome. Lancet 2:653\u2013654. https:\/\/doi.org\/10.1016\/s0140-6736(77)92516-8. PMID: 71464","DOI":"10.1016\/s0140-6736(77)92516-8"},{"key":"4172_CR133","doi-asserted-by":"publisher","unstructured":"Pearce CJ, Isaacs AJ, Gomez J (1977) Treatment of Cushing\u2019s disease with cyproheptadine. Lancet 11:1368\u20131369. https:\/\/doi.org\/10.1016\/s0140-6736(77)92585-5. PMID: 69087","DOI":"10.1016\/s0140-6736(77)92585-5"},{"key":"4172_CR134","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/0024-3205(68)90192-6","volume":"7","author":"G Curzon","year":"1968","unstructured":"Curzon G, Green AR (1968) Effect of hydrocortisone on rat brain 5-hydroxytryptamine. Life Sci 7:657\u2013663. https:\/\/doi.org\/10.1016\/0024-3205(68)90192-6","journal-title":"Life Sci"},{"key":"4172_CR135","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/2201095a0","volume":"220","author":"AR Green","year":"1968","unstructured":"Green AR, Curzon G (1968) Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature 220:1095\u20131097. https:\/\/doi.org\/10.1038\/2201095a0PMID: 5749362","journal-title":"Nature"},{"key":"4172_CR136","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0031-6989(69)80025-1","volume":"1","author":"U Scapagnini","year":"1969","unstructured":"Scapagnini U, Preziosi P, De Schaepdryver A (1969) Influence of restraint stress, corticosterone and betamethasone on brain amine levels. Pharmacol Res Commun 1:63\u201369. https:\/\/doi.org\/10.1016\/S0031-6989(69)80025-1","journal-title":"Pharmacol Res Commun"},{"key":"4172_CR137","doi-asserted-by":"publisher","unstructured":"Green AR, Woods HF, Knott PG, Curzon G (1975) Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature 255:170. https:\/\/doi.org\/10.1038\/255170a0. PMID: 1128686","DOI":"10.1038\/255170a0"},{"key":"4172_CR138","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/228073a0","volume":"228","author":"O Benkert","year":"1970","unstructured":"Benkert O, Matussek N (1970) Influence of hydrocorticosterone and glucagon on liver tyrosine transaminase and on brain tyrosine, norepinephrine and serotonin. Nature 228:73\u201375. https:\/\/doi.org\/10.1038\/228073a0PMID: 4393967","journal-title":"Nature"},{"key":"4172_CR139","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/253566a0","volume":"253","author":"J Hillier","year":"1975","unstructured":"Hillier J, Hillier JG, Redfern PH (1975) Liver tryptophan pyrrolase activity and metabolism of brain 5-HT in rat. Nature 253:566\u2013567. https:\/\/doi.org\/10.1038\/253566a0PMID: 1117992","journal-title":"Nature"},{"key":"4172_CR140","doi-asserted-by":"publisher","unstructured":"Millard SA, Costa E, Gal EM (1972) On the control of brain serotonin turnover rate by end product inhibition. Brain Res 40:545\u2013551. https:\/\/doi.org\/10.1016\/0006-8993(72)90160-6. PMID: 4337446","DOI":"10.1016\/0006-8993(72)90160-6"},{"key":"4172_CR141","doi-asserted-by":"publisher","unstructured":"Kawamura H, Ito A, Oishi T, Yanaga T (1984) Influence of glucocorticoids on brain serotonin metabolism in rats. Endocrinol Jpn 31:595\u2013603. https:\/\/doi.org\/10.1507\/endocrj1954.31.595. PMID: 6519033","DOI":"10.1507\/endocrj1954.31.595"},{"key":"4172_CR142","doi-asserted-by":"publisher","unstructured":"Inoue T, Koyama T (1996) Effects of acute and chronic administration of high-dose corticosterone and dexamethasone on regional brain dopamine and serotonin metabolism in rats. Prog Neuropsychopharmacol Biol Psychiatry 20:147\u2013156. https:\/\/doi.org\/10.1016\/0278-5846(95)00299-5. PMID: 8861184","DOI":"10.1016\/0278-5846(95)00299-5"},{"key":"4172_CR143","doi-asserted-by":"publisher","unstructured":"Curzon G, Green AR (1971) Regional and subcellular changes in the concentration of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat brain caused by hydrocortisone, DL-methyl-tryptophan l-kynurenine and immobilization. Br J Pharmacol 43:39\u201352. https:\/\/doi.org\/10.1111\/j.1476-5381.1971.tb07155.x. PMID: 5136463","DOI":"10.1111\/j.1476-5381.1971.tb07155.x"},{"key":"4172_CR144","doi-asserted-by":"publisher","unstructured":"Ulrich R, Yuwiler A, Geller E (1975) Effects of hydrocortisone on biogenic amine levels in the hypothalamus. Neuroendocrinology 19:259\u2013268. https:\/\/doi.org\/10.1159\/000122446. PMID: 1223662","DOI":"10.1159\/000122446"},{"key":"4172_CR145","doi-asserted-by":"publisher","unstructured":"Telegdy G, Vermes I (1975) Effect of adrenocortical hormones on activity of the serotoninergic system in limbic structures in rats. Neuroendocrinology 18:16\u201326. https:\/\/doi.org\/10.1159\/000122379. PMID: 1143627","DOI":"10.1159\/000122379"},{"key":"4172_CR146","doi-asserted-by":"publisher","unstructured":"Kov\u00e1cs GL, Kishonti J, Liss\u00e1k K, Telegdy G (1977) Dose-dependent dual effect of corticosterone on cerebral 5-HT metabolism. Neurochem Res 2:311\u2013322. https:\/\/doi.org\/10.1007\/BF00969361. PMID: 24272058","DOI":"10.1007\/BF00969361"},{"key":"4172_CR147","doi-asserted-by":"publisher","unstructured":"Kov\u00e1cs GL, Telegdy G, Liss\u00e1k K (1977) Dose-dependent action of corticosteroids on brain serotonin content and passive avoidance behavior. Horm Behav 8:155\u2013165. https:\/\/doi.org\/10.1016\/0018-506x(77)90032-0. PMID: 140845","DOI":"10.1016\/0018-506x(77)90032-0"},{"key":"4172_CR148","doi-asserted-by":"publisher","unstructured":"Luine VN, Spencer RL, McEwen BS (1993) Effects of chronic corticosterone ingestion on spatial memory performance and hippocampal serotonergic function. Brain Res 616:65\u201370. https:\/\/doi.org\/10.1016\/0006-8993(93)90193-q. PMID: 7689414","DOI":"10.1016\/0006-8993(93)90193-q"},{"key":"4172_CR149","doi-asserted-by":"publisher","unstructured":"Wolkowitz O, Sutton M, Koulu M, Labarca R, Wilkinson L, Doran A, Hauger R, Pickar D, Crawley J (1986) Chronic corticosterone administration in rats: behavioral and biochemical evidence of increased central dopaminergic activity. Eur J Pharmacol 122:329\u2013338. https:\/\/doi.org\/10.1016\/0014-2999(86)90413-9. PMID: 3709658","DOI":"10.1016\/0014-2999(86)90413-9"},{"key":"4172_CR150","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000121672","volume":"1","author":"CT McKennee","year":"1965","unstructured":"McKennee CT, Timiras PS, Quay WB (1965) Concentrations of 5-hydroxytryptamine in rat brain and pineal after adrenalectomy and cortisol administration. Neuroendocrinology 1:251\u2013256. https:\/\/doi.org\/10.1159\/000121672","journal-title":"Neuroendocrinology"},{"key":"4172_CR151","doi-asserted-by":"publisher","unstructured":"de Kloet ER, Kov\u00e1cs GL, Szab\u00f3 G, Telegdy G, Bohus B, Versteeg DH (1982) Decreased serotonin turnover in the dorsal hippocampus of rat brain shortly after adrenalectomy: selective normalization after corticosterone substitution. Brain Res 239:659\u2013663. https:\/\/doi.org\/10.1016\/0006-8993(82)90546-7. PMID: 7093709","DOI":"10.1016\/0006-8993(82)90546-7"},{"key":"4172_CR152","doi-asserted-by":"publisher","unstructured":"Zhou FC, Azmitia EC (1985) The effect of adrenalectomy and corticosterone on homotypic collateral sprouting of serotonergic fibers in hippocampus. Neurosci Lett 54:111\u2013116. https:\/\/doi.org\/10.1016\/s0304-3940(85)80064-1. PMID: 3991054","DOI":"10.1016\/s0304-3940(85)80064-1"},{"key":"4172_CR153","doi-asserted-by":"publisher","unstructured":"Azmitia EC Jr, Algeri S, Costa E (1970) In vivo conversion of 3H-L-tryptophan into 3H-serotonin in brain areas of adrenalectomized rats. Science 169:201\u2013203. https:\/\/doi.org\/10.1126\/science.169.3941.201. PMID: 5448706","DOI":"10.1126\/science.169.3941.201"},{"key":"4172_CR154","doi-asserted-by":"publisher","unstructured":"Mendelson SD, McEwen BS (1992) Quantitative autoradiographic analyses of the time course and reversibility of corticosterone-induced decreases in binding at 5-HT1A receptors in rat forebrain. Neuroendocrinology 56:881\u2013888. https:\/\/doi.org\/10.1159\/000126333. PMID: 1369598","DOI":"10.1159\/000126333"},{"key":"4172_CR155","doi-asserted-by":"publisher","unstructured":"Takao K, Nagatani T, Kitamura Y, Yamawaki S (1997) Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur J Pharmacol 333:123\u2013128. https:\/\/doi.org\/10.1016\/s0014-2999(97)01126-6. PMID: 9314024","DOI":"10.1016\/s0014-2999(97)01126-6"},{"key":"4172_CR156","doi-asserted-by":"publisher","unstructured":"Crayton JW, Joshi I, Gulati A, Arora RC, Wolf WA (1996) Effect of corticosterone on serotonin and catecholamine receptors and uptake sites in rat frontal cortex. Brain Res 728:260\u2013262. https:\/\/doi.org\/10.1016\/0006-8993(96)00189-8. PMID: 8864491","DOI":"10.1016\/0006-8993(96)00189-8"},{"key":"4172_CR157","doi-asserted-by":"publisher","unstructured":"Dickinson SL, Kennett GA, Curzon G (1985) Reduced-5-hydroxytryptamine-dependent behavior in rats following chronic corticosterone treatment. Brain Res 345:10\u201318. https:\/\/doi.org\/10.1016\/0006-8993(85)90830-3. PMID: 4063795","DOI":"10.1016\/0006-8993(85)90830-3"},{"key":"4172_CR158","doi-asserted-by":"publisher","unstructured":"Nausieda PA, Carvey PM, Weiner WJ (1982) Modification of central serotonergic and dopaminergic behaviors in the course of chronic corticosteroid administration. Eur J Pharmacol 78:335\u2013343. https:\/\/doi.org\/10.1016\/0014-2999(82)90035-8. PMID: 6978254","DOI":"10.1016\/0014-2999(82)90035-8"},{"key":"4172_CR159","doi-asserted-by":"publisher","unstructured":"Nausieda PA, Carvey PM, Braun A (1982) Long-term suppression of central serotonergic activity by corticosteroids: a possible model of steroid-responsive myoclonic disorders. Neurology 32:772\u2013775. https:\/\/doi.org\/10.1212\/wnl.32.7.772. PMID: 6979722","DOI":"10.1212\/wnl.32.7.772"},{"key":"4172_CR160","doi-asserted-by":"publisher","unstructured":"Bagdy G, Calogero AE, Aulakh CS, Szemeredi K, Murphy DL (1989) Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT1 agonists in the rat. Neuroendocrinology 50:241\u2013247. https:\/\/doi.org\/10.1159\/000125248. PMID: 2552339","DOI":"10.1159\/000125248"},{"key":"4172_CR161","doi-asserted-by":"publisher","unstructured":"Young AH, Goodwin GM, Dick H, Fink G (1994) Effects of glucocorticoids on 5-HT1A presynaptic function in the mouse. Psychopharmacology (Berl) 114:360\u2013364. https:\/\/doi.org\/10.1007\/BF02244859. PMID: 7838929","DOI":"10.1007\/BF02244859"},{"key":"4172_CR162","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0028-3908(92)90080-9","volume":"31","author":"AH Young","year":"1992","unstructured":"Young AH, MacDonald LM, St John H, Dick H, Goodwin GM (1992) The effects of corticosterone on 5-HT receptor function in rodents. Neuropharmacology 31:433\u2013438. https:\/\/doi.org\/10.1016\/0028-3908(92)90080-9PMID: 1388255","journal-title":"Neuropharmacology"},{"key":"4172_CR163","doi-asserted-by":"publisher","unstructured":"Haleem DJ (1992) Repeated corticosterone treatment attenuates behavioural and neuroendocrine responses to 8-hydroxy-2-(di-n-propylamino) tetralin in rats. Life Sci 51:PL225-230. https:\/\/doi.org\/10.1016\/0024-3205(92)90055-t. PMID: 1435084","DOI":"10.1016\/0024-3205(92)90055-t"},{"key":"4172_CR164","doi-asserted-by":"crossref","unstructured":"Jo\u00ebls M, Hesen W, de Kloet ER (1991) Mineralocorticoid hormones suppress serotonin-induced hyperpolarization of rat hippocampal CA1 neurons. J Neurosci 11(8):2288\u20132294. doi: 10.1523\/JNEUROSCI.11-08-02288.1991. PMID: 1869915","DOI":"10.1523\/JNEUROSCI.11-08-02288.1991"},{"key":"4172_CR165","doi-asserted-by":"publisher","unstructured":"Hesen W, Jo\u00ebls M (1996) Modulation of 5HT1A responsiveness in CA1 pyramidal neurons by in vivo activation of corticosteroid receptors. J Neuroendocrinol 8(6):433\u2013438. https:\/\/doi.org\/10.1046\/j.1365-2826.1996.04724.x. PMID: 8809673","DOI":"10.1046\/j.1365-2826.1996.04724.x"},{"key":"4172_CR166","doi-asserted-by":"publisher","unstructured":"Mueller NK, Beck SG (2000) Corticosteroids alter the 5-HT1A receptor-mediated response in CA1 hippocampal pyramidal cells. Neuropsychopharmacology 23(4):419\u2013427. https:\/\/doi.org\/10.1016\/S0893-133X(00)00134-2. PMID: 10989269","DOI":"10.1016\/S0893-133X(00)00134-2"},{"key":"4172_CR167","doi-asserted-by":"publisher","unstructured":"Fairchild G, Leitch MM, Ingram CD (2003) Acute and chronic effects of corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus. Neuropharmacology 45(7):925\u2013934. https:\/\/doi.org\/10.1016\/s0028-3908(03)00269-7. PMID: 14573385","DOI":"10.1016\/s0028-3908(03)00269-7"},{"key":"4172_CR168","doi-asserted-by":"publisher","unstructured":"Laaris N, Haj-Dahmane S, Hamon M, Lanfumey L (1995) Glucocorticoid receptor-mediated inhibition by corticosterone of 5-HT1A autoreceptor functioning in the rat dorsal raphe nucleus. Neuropharmacology 34(9):1201\u20131210. https:\/\/doi.org\/10.1016\/0028-3908(95)00095-n. PMID: 8532191","DOI":"10.1016\/0028-3908(95)00095-n"},{"key":"4172_CR169","doi-asserted-by":"publisher","unstructured":"McAllister-Williams RH, Massey AE, Fairchild G (2007) Repeated cortisol administration attenuates the EEG response to buspirone in healthy volunteers: evidence for desensitization of the 5-HT1A autoreceptor. J Psychopharmacol 21(8):826\u2013832. https:\/\/doi.org\/10.1177\/0269881107078292. PMID: 17715208","DOI":"10.1177\/0269881107078292"},{"key":"4172_CR170","doi-asserted-by":"publisher","unstructured":"Mendelson SD, McEwen BS (1992) Autoradiographic analyses of the effects of adrenalectomy and corticosterone on 5-HT1A and 5-HT1B receptors in the dorsal hippocampus and cortex of the rat. Neuroendocrinology 55:444\u2013450. https:\/\/doi.org\/10.1159\/000126160. PMID: 1533016","DOI":"10.1159\/000126160"},{"key":"4172_CR171","doi-asserted-by":"publisher","unstructured":"Biegon A, Rainbow TC, McEwen BS (1985) Corticosterone modulation of neurotransmitter receptors in rat hippocampus: a quantitative autoradiographic study. Brain Res 332:309\u2013314. https:\/\/doi.org\/10.1016\/0006-8993(85)90599-2. PMID: 2986762","DOI":"10.1016\/0006-8993(85)90599-2"},{"key":"4172_CR172","doi-asserted-by":"publisher","unstructured":"de Kloet ER, Sybesma H, Reul HM (1986) Selective control by corticosterone of serotonin 1 receptor capacity in raphe-hippocampal system. Neuroendocrinology 42:513\u2013521. https:\/\/doi.org\/10.1159\/000124496. PMID: 3010158","DOI":"10.1159\/000124496"},{"key":"4172_CR173","doi-asserted-by":"publisher","unstructured":"Meijer OC, de Kloet ER (1994) Corticosterone suppresses the expression of 5-HT1A receptor mRNA in rat dentate gyrus. Eur J Pharmacol 266:255\u2013261. https:\/\/doi.org\/10.1016\/0922-4106(94)90134-1. PMID: 8174608","DOI":"10.1016\/0922-4106(94)90134-1"},{"key":"4172_CR174","doi-asserted-by":"publisher","unstructured":"Chalmers DT, Kwak SP, Mansour A, Akil H, Watson SJ (1993) Corticosteroids regulate brain hippocampal 5-HT1A receptor mRNA expression. J Neurosci 13:914\u2013923. https:\/\/doi.org\/10.1523\/JNEUROSCI.13-03-00914.1993. PMID: 8441016","DOI":"10.1523\/JNEUROSCI.13-03-00914.1993"},{"key":"4172_CR175","doi-asserted-by":"publisher","unstructured":"Neumaier JF, Sexton TJ, Hamblin MW, Beck SG (2000) Corticosteroids regulate 5-HT(1A) but not 5-HT(1B) receptor mRNA in rat hippocampus. Mol Brain Res 82(1\u20132):65\u201373. https:\/\/doi.org\/10.1016\/s0169-328x(00)00181-9. PMID: 11042358","DOI":"10.1016\/s0169-328x(00)00181-9"},{"key":"4172_CR176","doi-asserted-by":"publisher","unstructured":"Le Corre S, Sharp T, Young AH, Harrison PJ (1997) Increase of 5-HT7 (serotonin-7) and 5-HT1A (serotonin-1A) receptor mRNA expression in rat hippocampus after adrenalectomy. Psychopharmacology (Berl) 130(4):368\u2013374. https:\/\/doi.org\/10.1007\/s002130050252. PMID: 9160853","DOI":"10.1007\/s002130050252"},{"key":"4172_CR177","doi-asserted-by":"publisher","unstructured":"Pivonello R, Waaijers M, Kros JM, Pivonello C, de Angelis C, Cozzolino A, Colao A, Lamberts SWJ, Hofland LJ (2017) Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine 57:314\u2013325. https:\/\/doi.org\/10.1007\/s12020-016-1107-2. PMID: 27738887","DOI":"10.1007\/s12020-016-1107-2"},{"key":"4172_CR178","doi-asserted-by":"publisher","unstructured":"Petrossians P, Thonnard AS, Beckers A (2010) Medical treatment in Cushing\u2019s syndrome: dopamine agonists and cabergoline. Neuroendocrinology 92Suppl1:116-9. https:\/\/doi.org\/10.1159\/000317716. PMID: 20829631","DOI":"10.1159\/000317716"},{"key":"4172_CR179","doi-asserted-by":"publisher","unstructured":"Bertrand A, Marec-Berard P, Raverot G, Trouillas J, Marabelle A (2010) Cabergoline therapy of paraneoplastic Cushing syndrome in children. Pediatr Blood Cancer 55:589\u2013590. https:\/\/doi.org\/10.1002\/pbc.22581. PMID: 20658641","DOI":"10.1002\/pbc.22581"},{"key":"4172_CR180","doi-asserted-by":"publisher","unstructured":"Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, Reznik Y, Bertherat J, Rohmer V, Briet C, Raingeard I, Castinetti F, Beckers A, Vroonen L, Maiter D, Cephise-Velayoudom FL, Nunes ML, Haissaguerre M, Tabarin A (2017) Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur J Endocrinol 176:305\u2013314. https:\/\/doi.org\/10.1530\/EJE-16-0662. PMID: 28007845","DOI":"10.1530\/EJE-16-0662"},{"key":"4172_CR181","doi-asserted-by":"publisher","unstructured":"Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, Ogura T, Date I, Hashimoto K, Makino H (2004) Effect of cabergoline treatment on Cushing\u2019s disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest 27:1055\u20131059. https:\/\/doi.org\/10.1007\/BF03345309. PMID: 15754738","DOI":"10.1007\/BF03345309"},{"key":"4172_CR182","doi-asserted-by":"publisher","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura L, Silva E, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13:123\u2013129. https:\/\/doi.org\/10.1007\/s11102-009-0209-8. PMID: 19943118","DOI":"10.1007\/s11102-009-0209-8"},{"key":"4172_CR183","doi-asserted-by":"publisher","unstructured":"Pivonello R, Ferone D, Lamberts SW, Colao A (2005) Cabergoline plus lanreotide for ectopic Cushing\u2019s syndrome. N Engl J Med 352:2457\u20132458. https:\/\/doi.org\/10.1056\/NEJM200506093522322. PMID: 15944436","DOI":"10.1056\/NEJM200506093522322"},{"key":"4172_CR184","doi-asserted-by":"publisher","unstructured":"van der Pas R, de Herder WW, Hofland LJ, Feelders RA (2012) New developments in the medical treatment of Cushing\u2019s syndrome. Endocr Relat Cancer 19:R205-R223. https:\/\/doi.org\/10.1530\/ERC-12-0191. PMID: 22936543","DOI":"10.1530\/ERC-12-0191"},{"key":"4172_CR185","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0893-133X(98)00103-1","volume":"21","author":"S Lindley","year":"1999","unstructured":"Lindley S, Bengoechea T, Schatzberg A (1999) Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology 21:399\u2013407. https:\/\/doi.org\/10.1016\/S0893-133X(98)00103-1","journal-title":"Neuropsychopharmacology"},{"key":"4172_CR186","doi-asserted-by":"publisher","unstructured":"Thomas DN, Post RM, Pert A (1994) Central and systemic corticosterone differentially affect dopamine and norepinephrine in the frontal cortex of the awake freely moving rat. Ann NY Acad Sci 746:467\u2013469. https:\/\/doi.org\/10.1111\/j.1749-6632.1994.tb39287.x. PMID: 7825916","DOI":"10.1111\/j.1749-6632.1994.tb39287.x"},{"key":"4172_CR187","doi-asserted-by":"publisher","unstructured":"Piazza PV, Roug\u00e9-Pont F, Deroche V, Maccari S, Simon H, Le Moal M (1996) Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci USA 93:8716\u20138720. https:\/\/doi.org\/10.1073\/pnas.93.16.8716. PMID: 8710937","DOI":"10.1073\/pnas.93.16.8716"},{"key":"4172_CR188","doi-asserted-by":"crossref","unstructured":"Graf EN, Wheeler RA, Baker DA, Ebben AL, Hill JE, McReynolds JR, Robble MA, Vranjkovic O, Wheeler DS, Mantsch JR, Gasser PJ (2013) Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 33:11800\u201311810. doi: 10.1523\/JNEUROSCI.1969-13.2013. PMID: 23864669","DOI":"10.1523\/JNEUROSCI.1969-13.2013"},{"key":"4172_CR189","doi-asserted-by":"publisher","unstructured":"Pacak K, Tjurmina O, Palkovits M, Goldstein DS, Koch CA, Hoff T, Chrousos GP (2002) Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study. Neuroendocrinology 76:148\u2013157. https:\/\/doi.org\/10.1159\/000064522. PMID: 12218347","DOI":"10.1159\/000064522"},{"key":"4172_CR190","doi-asserted-by":"publisher","unstructured":"de Villiers AS, Russell VA, Taljaard JJ (1992) Effect of corticosterone on noradrenergic nuclei in the pons-medulla and [3H]NA release from terminals in hippocampal slices. Neurochem Res 17:273\u2013280. https:\/\/doi.org\/10.1007\/BF00966670. PMID: 1620270","DOI":"10.1007\/BF00966670"},{"key":"4172_CR191","doi-asserted-by":"publisher","unstructured":"Faunt JE, Crocker AD (1988) Adrenocortical hormone status affects responses to dopamine receptor agonists. Eur J Pharmacol 152:255\u2013261. https:\/\/doi.org\/10.1016\/0014-2999(88)90720-0. PMID: 2906001","DOI":"10.1016\/0014-2999(88)90720-0"},{"key":"4172_CR192","first-page":"265","volume":"35","author":"EJ Nestler","year":"1989","unstructured":"Nestler EJ, Terwilliger RZ, Halm E (1989) Corticosterone increases protein tyrosine kinase activity in the locus coeruleus and other monoaminergic nuclei of rat brain. Mol Pharmacol 35:265\u2013270 PMID: 2927386","journal-title":"Mol Pharmacol"},{"key":"4172_CR193","doi-asserted-by":"publisher","unstructured":"Deroche V, Piazza PV, Maccari S, Le Moal M, Simon H (1992) Repeated corticosterone administration sensitizes the locomotor response to amphetamine. Brain Res 584:309\u2013313. https:\/\/doi.org\/10.1016\/0006-8993(92)90911-r. PMID: 1515947","DOI":"10.1016\/0006-8993(92)90911-r"},{"key":"4172_CR194","doi-asserted-by":"publisher","unstructured":"Ortiz J, DeCaprio JL, Kosten TA, Nestler EJ (1995) Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and glucocorticoid receptor in the ventral tegmental area. Neuroscience 67:383\u2013397. https:\/\/doi.org\/10.1016\/0306-4522(95)00018-e. PMID: 7675174","DOI":"10.1016\/0306-4522(95)00018-e"},{"key":"4172_CR195","doi-asserted-by":"publisher","unstructured":"Diaz R, \u00d6gren SO, Blum M, Fuxe K (1995) Prenatal corticosterone increases spontaneous and d-amphetamine induced locomotor activity and brain dopamine metabolism in prepubertal male and female rats. Neuroscience 66:467\u2013473. https:\/\/doi.org\/10.1016\/0306-4522(94)00605-5. PMID: 7477887","DOI":"10.1016\/0306-4522(94)00605-5"},{"key":"4172_CR196","doi-asserted-by":"publisher","unstructured":"Diaz R, Fuxe K, \u00d6gren SO (1997) Prenatal corticosterone treatment induces long-term changes in spontaneous and apomorphine-mediated motor activity in male and female rats. Neuroscience 81:129\u2013140. https:\/\/doi.org\/10.1016\/s0306-4522(97)00141-3. PMID: 9300406","DOI":"10.1016\/s0306-4522(97)00141-3"},{"key":"4172_CR197","doi-asserted-by":"publisher","unstructured":"Castall B, Marsden CD, Naylor RJ, Pycock CJ (1977) Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Res 123:89\u2013111. https:\/\/doi.org\/10.1016\/0006-8993(77)90645-x. PMID: 300267","DOI":"10.1016\/0006-8993(77)90645-x"},{"key":"4172_CR198","doi-asserted-by":"publisher","unstructured":"Cador M, Dulluc J, Morm\u00e8de JP (1993) Modulation of the locomotor response to amphetamine by corticosterone. Neuroscience 56:981\u2013988. https:\/\/doi.org\/10.1016\/0306-4522(93) 90144-5. PMID: 8284048","DOI":"10.1016\/0306-4522"},{"key":"4172_CR199","doi-asserted-by":"publisher","unstructured":"Rivet JM, Stinus L, LeMoal M, Morm\u00e8de P (1989) Behavioral sensitization to amphetamine is dependent on corticosteroid receptor activation. Brain Res 498:149\u2013153. https:\/\/doi.org\/10.1016\/0006-8993(89)90411-3. PMID: 2790466","DOI":"10.1016\/0006-8993(89)90411-3"},{"key":"4172_CR200","doi-asserted-by":"publisher","unstructured":"Biron D, Dauphin C, Di Paolo T (1992) Effects of adrenalectomy and glucocorticoids on rat brain dopamine receptors. Neuroendocrinology 55:468\u2013476. https:\/\/doi.org\/10.1159\/000126158. PMID: 1314340","DOI":"10.1159\/000126158"},{"key":"4172_CR201","doi-asserted-by":"publisher","unstructured":"Barrot M, Abrous DN, Marinelli M, Roug\u00e9-Pont F, Le Moal M, Piazza PV (2001) Influence of glucocorticoids on dopaminergic transmission in the rat dorsolateral striatum. Eur J Neurosci 13:812\u2013818. https:\/\/doi.org\/10.1046\/j.1460-9568.2001.01434.x. PMID: 11207816","DOI":"10.1046\/j.1460-9568.2001.01434.x"},{"key":"4172_CR202","doi-asserted-by":"publisher","unstructured":"Faunt JE, Crocker AD (1989) Effects of adrenalectomy on responses mediated by dopamine D-1 and D-2 receptors. Eur J Pharmacol 162:237\u2013244. https:\/\/doi.org\/10.1016\/0014-2999(89)90286-0. PMID: 2566498","DOI":"10.1016\/0014-2999(89)90286-0"},{"key":"4172_CR203","doi-asserted-by":"publisher","unstructured":"Heaney AP, Hunter SJ, Sheridan B, Atkinson AB (1999) Increased pressor response to noradrenaline in pituitary dependent Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 51:293\u2009\u2013\u200999. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00766.x. PMID: 10469008","DOI":"10.1046\/j.1365-2265.1999.00766.x"},{"key":"4172_CR204","doi-asserted-by":"publisher","unstructured":"Pacak K, Palkovits M, Kvetnansky R, Matern P, Hart C, Kopin IJ, Goldstein DS (1995) Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats. Endocrinology 136:4814\u20134819. https:\/\/doi.org\/10.1210\/endo.136.11.7588211. PMID: 7588211","DOI":"10.1210\/endo.136.11.7588211"},{"key":"4172_CR205","doi-asserted-by":"publisher","unstructured":"Van Loon GR, Sole MJ, Kamble A, Kim C, Green S (1977) Differential responsiveness of central noradrenergic and dopaminergic neuron tyrosine hydroxylase to hypophysectomy, ACTH and glucocorticoid administration. Ann NY Acad Sci 297:284\u2013294. https:\/\/doi.org\/10.1111\/j.1749-6632.1977.tb41861.x. PMID: 29550","DOI":"10.1111\/j.1749-6632.1977.tb41861.x"},{"key":"4172_CR206","doi-asserted-by":"publisher","unstructured":"Jo\u00ebls M, de Kloet ER (1989) Effects of glucocorticoids and norepinephrine on the excitability in the hippocampus. Science 245:1502\u20131505. https:\/\/doi.org\/10.1126\/science.2781292. PMID: 2781292","DOI":"10.1126\/science.2781292"},{"key":"4172_CR207","doi-asserted-by":"publisher","unstructured":"Krugers HJ, Karst H, Joels M (2012) Interactions between noradrenaline and corticosteroids in the brain: from electrical activity to cognitive performance. Front Cell Neurosci 6:15. https:\/\/doi.org\/10.3389\/fncel.2012.00015. PMID: 22509154","DOI":"10.3389\/fncel.2012.00015"},{"key":"4172_CR208","doi-asserted-by":"publisher","unstructured":"Crespo I, Santos A, G\u00f3mez-Ans\u00f3n B, L\u00f3pez-Mourelo O, Pires P, Vives-Gilabert Y, Webb SM, Resmini E (2016) Brain metabolite abnormalities in ventromedial prefrontal cortex are related to duration of hypercortisolism and anxiety in patients with Cushing\u2019s syndrome. Endocrine 53:848\u2013856. https:\/\/doi.org\/10.1007\/s12020-016-0963-0. PMID: 27103571","DOI":"10.1007\/s12020-016-0963-0"},{"key":"4172_CR209","doi-asserted-by":"publisher","unstructured":"Kula J, Blasiak A, Czerw A, Tylko G, Sowa J, Hess G (2016) Short-term repeated corticosterone administration enhances glutamatergic but not GABAergic transmission in the rat motor cortex. Pflugers Arch 468:679\u2013691. https:\/\/doi.org\/10.1007\/s00424-015-1773-6. PMID: 26696244","DOI":"10.1007\/s00424-015-1773-6"},{"key":"4172_CR210","first-page":"17","volume":"37Suppl2","author":"MJ Owens","year":"2003","unstructured":"Owens MJ, Nemeroff CB (2003) Pharmacology of valproate. Psychopharmacol Bull 37Suppl2:17\u201324 PMID: 14624230","journal-title":"Psychopharmacol Bull"},{"key":"4172_CR211","doi-asserted-by":"publisher","unstructured":"Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1982) Sodium valproate and heterogeneity of pituitary dependent Cushing\u2019s syndrome. Lancet 1:1253. https:\/\/doi.org\/10.1016\/s0140-6736(82)92383-2. PMID: 6123012","DOI":"10.1016\/s0140-6736(82)92383-2"},{"key":"4172_CR212","doi-asserted-by":"publisher","unstructured":"Koppeschaar HP, Croughs RJ, van\u2019t Verlaat JW, Hendriks MJ, Arts CJ, Thijssen JH, Schwarz F (1984) Successful treatment with sodium valproate of a patient with Cushing\u2019s disease and gross enlargement of the pituitary. Acta Endocrinol (Copenh) 107:471\u2013475. https:\/\/doi.org\/10.1530\/acta.0.1070471. PMID: 6097074","DOI":"10.1530\/acta.0.1070471"},{"key":"4172_CR213","doi-asserted-by":"publisher","unstructured":"Colao A, Pivonello R, Tripodi FS, Orio F Jr, Ferone D, Cerbone G, Di Somma C, Merola B, Lombardi G (1997) Failure of long-term therapy with sodium valproate in Cushing\u2019s disease. J Endocrinol Invest 20:387\u2013392. https:\/\/doi.org\/10.1007\/BF03347989. PMID: 9309536","DOI":"10.1007\/BF03347989"},{"issue":"82","key":"4172_CR214","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0140-6736","volume":"1","author":"A Allolio","year":"1982","unstructured":"Allolio A, Winkelmann W, Kaulen D, Hipp FX, Mies R (1982) Valproate in Cushing\u2019s syndrome. Lancet 1(82):171. https:\/\/doi.org\/10.1016\/s0140-6736. )90422-6, PMID: 6119549","journal-title":"Lancet"},{"key":"4172_CR215","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/BF01726927","volume":"66","author":"M Reincke","year":"1988","unstructured":"Reincke M, Allolio B, Kaulen D, Jaursch-Hancke C, Winkelmann W (1988) The effect of sodium valproate in Cushing\u2019s disease, Nelson\u2019s syndrome and Addison\u2019s disease. Klin Wochenschr 66:686\u2013689 PMID: 2845188","journal-title":"Klin Wochenschr"},{"key":"4172_CR216","doi-asserted-by":"publisher","unstructured":"Giordano R, Berardelli R, Karamouzis I, D\u2019Angelo V, Picu A, Zichi C, Fussotto B, Manzo M, Mengozzi G, Ghigo E, Arvat E (2013) Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing\u2019s syndrome. Pituitary 16:363\u2013369. https:\/\/doi.org\/10.1007\/s11102-012-0433-5. PMID: 22983690","DOI":"10.1007\/s11102-012-0433-5"},{"key":"4172_CR217","doi-asserted-by":"publisher","unstructured":"McMillan PJ, Wilkinson CW, Greenup L, Raskind MA, Peskind ER, Leverenz JB (2004) Chronic cortisol exposure promotes the development of a GABAergic phenotype in the primate hippocampus. J Neurochem 91:843\u2013851. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02760.x. PMID: 15525338","DOI":"10.1111\/j.1471-4159.2004.02760.x"},{"key":"4172_CR218","doi-asserted-by":"publisher","unstructured":"Orchinik M, Weiland NG, McEwen BS (1995) Chronic exposure to stress levels of corticosterone alters GABAA receptor subunit mRNA levels in rat hippocampus. Mol Brain Res 34:29\u201337. https:\/\/doi.org\/10.1016\/0169-328x(95)00118-c. PMID: 8750858","DOI":"10.1016\/0169-328x(95)00118-c"},{"key":"4172_CR219","doi-asserted-by":"publisher","unstructured":"Orchinik M, Carroll SS, Li YH, McEwen BS, Weiland NG (2001) Heterogeneity of hippocampal GABA(A) receptors: regulation by corticosterone. J Neurosci 21:330\u2013339. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-01-00330.2001. PMID: 11150350","DOI":"10.1523\/JNEUROSCI.21-01-00330"},{"key":"4172_CR220","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0006-8993(85)90641-9","volume":"339","author":"MD Majewska","year":"1985","unstructured":"Majewska MD, Bisserbe JC, Eskay RL (1985) Glucocorticoids are modulators of GABAA receptors in brain. Brain Res 339:178\u2013182. https:\/\/doi.org\/10.1016\/0006-8993(85)90641-9PMID: 2992695","journal-title":"Brain Res"},{"key":"4172_CR221","doi-asserted-by":"publisher","unstructured":"Kendall DA, McEwen BS, Enna SJ (1982) The influence of ACTH and corticosterone on [3H]GABA receptor binding in rat brain. Brain Res 236:365\u2013374. https:\/\/doi.org\/10.1016\/0006-8993(82)90721-1. PMID: 6279241","DOI":"10.1016\/0006-8993(82)90721-1"},{"key":"4172_CR222","doi-asserted-by":"publisher","unstructured":"Miller AL, Chaptal C, McEwen BS, Peck EJ Jr (1978) Modulation of high affinity GABA uptake into hippocampal synaptosomes by glucocorticoids. Psychoneuroendocrinology 3:155\u2013164. https:\/\/doi.org\/10.1016\/0306-4530(78)90003-3. PMID: 704749","DOI":"10.1016\/0306-4530(78)90003-3"},{"key":"4172_CR223","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511543661","volume-title":"The brain and behavior: an introduction to behavioral neuroanatomy","author":"DL Clark","year":"2005","unstructured":"Clark DL, Boutros NN, Mendez MF (2005) The brain and behavior: an introduction to behavioral neuroanatomy, 2nd edn. Cambridge University Press, Cambridge","edition":"2"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-024-04172-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-024-04172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:45:54Z","timestamp":1720583154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-024-04172-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":223,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4172"],"URL":"https:\/\/doi.org\/10.1007\/s11064-024-04172-2","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}